NurrOn Pharmaceuticals
NurrOn Pharmaceuticals
  • Home
  • About Us
  • Technology
  • Media Relation
  • Newsroom
  • Contact
  • More
    • Home
    • About Us
    • Technology
    • Media Relation
    • Newsroom
    • Contact

  • Home
  • About Us
  • Technology
  • Media Relation
  • Newsroom
  • Contact

Media Relation

November 26, 2024

NurrOn, HanAll Biopharma and Daewoong Pharmaceutical announced successful completion of a first-in-human Phase 1 clinical study of ATH-399A.

  

AP News: HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce

Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for

Parkinson's Disease

Yahoo! Finance: HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals

Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy

for Parkinson's Disease

October 12, 2023

 NurrOn, HanAllBiopharma and Daewoong Pharmaceutical initiated first-in-human Phase I clinical study of ATH-399A. 

  

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 – WSJ

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 – Bloomberg

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 (yahoo.com)

March 29, 2023

NurrOn entered into co-development agreement with HanAll Biopharma and Daewoong Pharmaceuticals to develop ATH-399A for Parkinson’s disease.

https://www.prnewswire.com/news-releases/hanall-biopharma-and-daewoong-pharmaceutical-enter-into-co-development-agreement-with-nurron-pharmaceuticals-to-develop-therapy-for-parkinsons-disease-301834508.html

December 1, 2022

NurrOn received the award of the translational pipeline program 2022 for a Phase I trial of ATH-399A from Michael J. Fox Foundation.

https://www.michaeljfox.org/grant/development-nurr1-activator-novel-therapeutic-parkinsons-disease

Copyright © 2024 NurrOn Pharmaceuticals - All Rights Reserved.

Powered by GoDaddy Website Builder

  • Home
  • About Us
  • Technology
  • Media Relation
  • Newsroom
  • Contact